Participant flow

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate · Source last updated 2022-01-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.

   id

   FG000

   title

   Imatinib Mesylate

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         125

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         125

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice